C 
China Resources Double-Crane Pharmaceutical Co 600062.SS · CNY
Health Care · Shanghai · 🇨🇳 China
15.84
-1.43%
Close of 9 Nov 2026, in CNY
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
At a glance
Figures in CNY, from our data supplier.
Revenue
CN¥11.00bn
FY2016FY2025
Net income
CN¥1.65bn
FY2016FY2025
Free cash flow
CN¥869.9m
FY2016FY2025
Shareholders' equity
CN¥11.63bn
FY2016FY2025
Income statement
Fiscal years
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | CN¥11.00bn | CN¥11.21bn | CN¥11.31bn | CN¥9.63bn | CN¥9.11bn | CN¥8.50bn | CN¥9.38bn | CN¥8.23bn | CN¥6.42bn | CN¥5.49bn |
| Gross profit | CN¥6.38bn | CN¥6.38bn | CN¥6.41bn | CN¥5.32bn | CN¥5.06bn | CN¥5.35bn | CN¥5.93bn | CN¥5.20bn | CN¥3.67bn | CN¥2.90bn |
| Research and development | CN¥531.6m | CN¥725.6m | CN¥627.8m | CN¥482.5m | CN¥409.6m | CN¥291.0m | CN¥202.0m | CN¥144.7m | CN¥152.2m | CN¥120.6m |
| Operating income | CN¥1.94bn | CN¥1.83bn | CN¥1.88bn | CN¥1.43bn | CN¥1.14bn | CN¥1.23bn | CN¥1.26bn | CN¥1.19bn | CN¥1.06bn | CN¥847.3m |
| Net income | CN¥1.65bn | CN¥1.63bn | CN¥1.67bn | CN¥1.18bn | CN¥935.7m | CN¥1.01bn | CN¥1.06bn | CN¥968.6m | CN¥842.6m | CN¥714.2m |
| Diluted earnings per share | 1.59 | 1.58 | 1.63 | 1.11 | 0.90 | 0.96 | 1.01 | 0.93 | 0.81 | 0.68 |
Balance sheet
At each fiscal year end
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | CN¥17.01bn | CN¥16.69bn | CN¥15.43bn | CN¥14.48bn | CN¥13.68bn | CN¥12.42bn | CN¥11.28bn | CN¥10.31bn | CN¥9.44bn | CN¥8.24bn |
| Cash and short-term investments | CN¥2.42bn | CN¥2.85bn | CN¥3.46bn | CN¥2.83bn | CN¥3.64bn | CN¥3.26bn | CN¥2.60bn | CN¥1.98bn | CN¥1.25bn | CN¥1.49bn |
| Total liabilities | CN¥4.51bn | CN¥5.57bn | CN¥3.64bn | CN¥3.75bn | CN¥3.20bn | CN¥3.04bn | CN¥2.60bn | CN¥2.40bn | CN¥1.59bn | CN¥1.20bn |
| Debt | CN¥1.16bn | CN¥1.18bn | CN¥59.9m | CN¥265.0m | CN¥64.9m | CN¥6.6m | CN¥64.9m | CN¥82.0m | CN¥322,118 | — |
| Shareholders' equity | CN¥11.63bn | CN¥10.41bn | CN¥11.09bn | CN¥10.02bn | CN¥9.91bn | CN¥9.29bn | CN¥8.60bn | CN¥7.84bn | CN¥7.46bn | CN¥6.69bn |
| Shares outstanding | 1,034m | 1,028m | 1,022m | 1,062m | 1,043m | 1,043m | 1,043m | 1,044m | 1,043m | 1,043m |
Cash flow
Fiscal years
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | CN¥1.49bn | CN¥1.83bn | CN¥1.65bn | CN¥1.34bn | CN¥1.34bn | CN¥1.36bn | CN¥1.44bn | CN¥1.47bn | CN¥1.19bn | CN¥771.2m |
| Capital spending | −CN¥619.6m | −CN¥637.5m | −CN¥614.3m | −CN¥525.5m | −CN¥491.7m | −CN¥348.1m | −CN¥241.6m | −CN¥228.7m | −CN¥154.8m | −CN¥110.0m |
| Free cash flow | CN¥869.9m | CN¥1.19bn | CN¥1.04bn | CN¥816.1m | CN¥849.2m | CN¥1.01bn | CN¥1.20bn | CN¥1.24bn | CN¥1.03bn | CN¥661.2m |
| Dividends paid | −CN¥716.1m | −CN¥1.48bn | −CN¥300.5m | −CN¥799.2m | −CN¥302.5m | −CN¥317.1m | −CN¥291.1m | −CN¥91.1m | −CN¥193.7m | −CN¥184.7m |
Latest quarters
By quarter end
| Jun 2026 | Mar 2026 | Dec 2025 | Sept 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sept 2024 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | CN¥2.81bn | CN¥2.81bn | CN¥2.72bn | CN¥2.54bn | CN¥2.66bn | CN¥3.08bn | CN¥2.66bn | CN¥2.62bn |
| Gross profit | CN¥1.61bn | CN¥1.66bn | CN¥1.47bn | CN¥1.49bn | CN¥1.56bn | CN¥1.86bn | CN¥1.38bn | CN¥1.52bn |
| Operating income | CN¥505.8m | CN¥583.3m | CN¥298.8m | CN¥390.1m | CN¥562.8m | CN¥639.0m | CN¥247.5m | CN¥416.5m |
| Net income | CN¥461.4m | CN¥484.9m | CN¥297.4m | CN¥374.0m | CN¥468.8m | CN¥506.7m | CN¥230.7m | CN¥350.5m |
| Diluted earnings per share | 0.45 | 0.47 | 0.29 | 0.36 | 0.45 | 0.49 | 0.22 | 0.34 |
| Cash from operations | — | — | CN¥342.0m | CN¥487.0m | CN¥345.0m | CN¥317.0m | — | CN¥527.0m |
| Capital spending | −CN¥138.0m | −CN¥108.0m | −CN¥186.0m | −CN¥192.0m | −CN¥113.0m | −CN¥126.0m | −CN¥115.0m | −CN¥307.0m |
| Free cash flow | — | — | CN¥156.0m | CN¥295.0m | CN¥232.0m | CN¥191.0m | — | CN¥220.0m |
| Total assets | CN¥18.36bn | CN¥18.01bn | CN¥17.01bn | CN¥17.01bn | CN¥16.74bn | CN¥17.29bn | CN¥16.69bn | CN¥16.55bn |
| Cash and short-term investments | — | — | CN¥2.42bn | CN¥2.42bn | CN¥2.53bn | CN¥3.12bn | CN¥2.85bn | CN¥2.71bn |
| Debt | CN¥1.01bn | CN¥1.54bn | CN¥1.14bn | CN¥49.0m | CN¥1.11bn | CN¥1.15bn | CN¥1.15bn | CN¥665.5m |
| Shareholders' equity | CN¥12.25bn | CN¥12.12bn | CN¥11.63bn | CN¥11.32bn | CN¥11.04bn | CN¥10.92bn | CN¥10.41bn | CN¥10.19bn |
Financial ratios
Data as of 28 Sept 2026
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | |
|---|---|---|---|---|---|---|---|
| Gross margin | 58.0% | 56.9% | 56.6% | 55.3% | 55.6% | 62.9% | — |
| Operating margin | 17.7% | 16.4% | 16.6% | 14.8% | 12.5% | 14.5% | — |
| Net margin | 15.0% | 14.5% | 14.8% | 12.3% | 10.3% | 11.8% | — |
| Return on equity | 14.2% | 15.6% | 15.1% | 11.8% | 9.4% | 10.8% | — |
| Return on assets | 9.7% | 9.8% | 10.8% | 8.1% | 6.8% | 8.1% | — |
| Free cash flow yield | 12.8% | 15.0% | 13.9% | 11.0% | 11.0% | 10.2% | — |
| Revenue growth | -1.9% | -0.9% | 17.5% | 5.6% | 7.1% | -9.3% | — |
| Earnings growth | 1.2% | -2.6% | 41.6% | 26.1% | -6.9% | -4.7% | — |
| Current ratio | 2.35x | 1.87x | 2.42x | 2.38x | 2.75x | 2.55x | — |
| Debt to equity | 0.10x | 0.11x | 0.00x | 0.02x | 0.00x | — | 0.01x |
| Equity ratio | 68.4% | 62.4% | 71.9% | 69.2% | 72.4% | 74.9% | — |
| Interest coverage | 57.90x | 109.39x | 110.86x | 119.42x | 90.59x | 291.91x | — |
| R&D as a share of sales | 4.8% | 6.5% | 5.6% | 5.0% | 4.5% | 3.4% | — |
| Buybacks as a share of market value | -0.6% | -0.6% | 3.8% | -1.8% | -0.0% | 0.0% | — |
Growth per year
Compound annual rate
| 3 years | 5 years | 10 years | |
|---|---|---|---|
| Revenue | 4.6% | 5.3% | 7.9% |
| Operating income | 10.9% | 9.6% | 9.8% |
| Net income | 11.8% | 10.4% | 9.6% |
Average margins
Over each period
| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Gross margin | 57.5% | 56.8% | 57.4% | 57.9% |
| Operating margin | 17.0% | 16.4% | 15.6% | 15.3% |
| Net margin | 14.7% | 14.2% | 13.3% | 12.9% |
Valuation history
At each fiscal year end
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Price to earnings | 11.5 | 12.5 | 11.4 | 16.1 | 14.9 | 12.4 | 12.9 | 13.0 | 25.6 | 22.5 |
| Price to sales | 1.7 | 1.8 | 1.7 | 2.0 | 1.5 | 1.5 | 1.4 | 1.5 | 3.4 | 2.9 |
Dividends and splits
Per share, in the currency the company pays
Paid for 10 years. Last went ex-dividend on 28 Jul 2026.
| FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | |
|---|---|---|---|---|---|---|---|---|
| Paid in the year | 0.379 | 0.10 | 0.357 | 0.289 | 0.769 | 0.29 | 0.304 | 0.279 |
- 6-for-5 split · 16 Aug 2018
- 6-for-5 split · 17 Jul 2017
- 6-for-5 split · 16 Jul 2009
- 1-to-1 reverse split · 6 Apr 2006
- 13-for-10 split · 13 May 2002
- 13-for-10 split · 27 Apr 2000
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.